| ASSET | YEAR | % RETURN |
|---|---|---|
MaxLinear (MXL) | 2026 | 437.3% |
Erasca (ERAS) | 2026 | 416.98% |
Bandwidth (BAND) | 2026 | 405.09% |
Ichor (ICHR) | 2026 | 402.55% |
Immunitybio (IBRX) | 2026 | 339.11% |
Penguin Solutions (PENG) | 2026 | 309.41% |
Ultra Clean (UCTT) | 2026 | 306.24% |
Veradermics (MANE) | 2026 | 267.38% |
AXT (AXTI) | 2026 | 263.66% |
Aehr Test Systems (AEHR) | 2026 | 262.56% |
Definium Therapeutics (DFTX) | 2026 | 258.89% |
Silicon Motion Technology (SIMO) | 2026 | 244.97% |
Tango Therapeutics (TNGX) | 2026 | 244.86% |
Enliven Therapeutics (ELVN) | 2026 | 236.65% |
Applied Opt (AAOI) | 2026 | 236.25% |
Alumis (ALMS) | 2026 | 210.13% |
Sellas Life Sciences (SLS) | 2026 | 203.6% |
Spyre Therapeutics (SYRE) | 2026 | 201.43% |
BlackBerry (BB) | 2026 | 199.21% |
Vishay Intertechnology (VSH) | 2026 | 199.17% |
Maase (MAAS) | 2026 | 196.3% |
Twist Bioscience (TWST) | 2026 | 195.21% |
Iridium Communications (IRDM) | 2026 | 191.55% |
Oruka Therapeutics (ORKA) | 2026 | 191.22% |
P3 Health Partners (PIII) | 2026 | 178.53% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.